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Modulation of Serum Antinuclear Antibody Levels 
by Levamisole Treatment in Patients With 
Oral Lichen Planus
Hung-Pin Lin,1 Yi-Ping Wang,1,2,3 Jean-San Chia,1,2,3,4 Andy Sun2,3*
Background/Purpose: Serum autoantibodies, including antinuclear antibodies (ANAs), have been found
in patients with oral lichen planus (OLP). This study evaluated whether Taiwanese OLP patients had 
significantly higher frequencies of serum ANAs than healthy control subjects, and whether levamisole
treatment could modulate the antibody levels.
Methods: This study used an indirect immunofluorescence technique to measure the baseline serum 
levels of ANA in a group of 583 Taiwanese OLP patients and 53 healthy control subjects. Seventy-nine
ANA-positive OLP patients were treated with levamisole under a regular follow-up schedule in our dental
clinic, and their serum ANA levels were measured after treatment.
Results: We found that the frequencies of serum ANA in patients with OLP (23.2%), erosive OLP (EOLP,
23.8%), major EOLP (31.5%), and minor EOLP (18.1%) were all significantly higher than that (5.7%) in
healthy control subjects. In addition, major EOLP patients had a significantly higher serum ANA-positive
rate than minor EOLP or non-erosive OLP patients. Of 135 ANA-positive OLP patients, 79 were treated
with levamisole under a regular follow-up schedule. We found that treatment with levamisole for a period
of 2–38 months (mean, 12 ± 9 months) effectively reduced the high mean serum ANA titer (557 ± 98) at
baseline to an undetectable level (0) in all ANA-positive OLP patients, regardless of different high initial
serum titers of ANA.
Conclusion: There was a significantly higher frequency of serum ANA (23.2%) in Taiwanese OLP patients
than in healthy control subjects. Treatment with levamisole for 2–38 months reduced the high serum 
ANA to an undetectable level, and significantly improved the signs and symptoms in all treated OLP 
patients.
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Oral lichen planus (OLP) is a chronic inflamma-
tory oral mucosal disease frequently found in 
the dental clinic. Both antigen-specific and non-
specific mechanisms are involved in OLP. Antigen-
specific mechanisms include antigen presentation
by basal keratinocytes and antigen-specific kera-
tinocyte killing by CD8+ cytotoxic T lymphocytes.
Non-specific mechanisms include mast cell de-
granulation and matrix metalloproteinase acti-
vation in OLP lesions.1 Through mast cell/T-cell
interactions in OLP lesions, mast-cell-released
cytokines, chemokines and matrix metallopro-
teinases can promote T-cell activation, migration,
proliferation and differentiation.2 OLP is histolog-
ically characterized by liquefaction degeneration
of basal epithelial cells, and marked subepithe-
lial infiltration of mononuclear cells that are pre-
dominantly CD8+. CD4+ cells are observed mainly
in the deep lamina propria.3 An increase in his-
tocompatibility leukocyte antigen (HLA)-DR-
positive CD3+ cells in both the local lesional
tissues and peripheral lymphocytes also indicates
T-cell activation in OLP.4,5 The above findings
suggest that OLP is a T-cell-mediated inflamma-
tory disease.
Levamisole is an immunomodulator that can
modulate T-cell-mediated immunity.6–9 Our pre-
vious studies have found that levamisole can
also modulate abnormal serum interleukin (IL)-
6, IL-8, tumor necrosis factor (TNF)-α, anti-basal
cell antibody (anti-BCA), and antinuclear anti-
body (ANA) levels to normal in patients with
OLP or erosive OLP (EOLP).6–9
The presence of serum autoantibodies includ-
ing anti-epithelial cell, ANA, smooth muscle anti-
body (SMA), antimitochondrial antibody (AMA),
gastric parietal cell antibody (GPCA), thyroglobu-
lin antibody (TGA), thyroid microsomal antibody
(TMA), and anti-desmogleins 1 and 3 antibodies
has been shown in several different groups of
OLP patients.9–15
In this study, we examined the frequencies of
serum ANA in a group of 583 Taiwanese OLP 
patients and in 53 healthy control subjects. We
tried to establish whether there was a significantly
higher frequency of serum ANA in Taiwanese OLP
patients than in healthy control subjects, and
whether levamisole treatment could modulate
serum ANA levels.
Patients and Methods
Patients and control subjects
The study group consisted of 583 OLP patients
(102 men and 481 women; age range, 22–88
years; mean age, 55.0 years) without LP of other
mucosal or skin surfaces. The normal control
group consisted of 53 healthy subjects (8 men
and 45 women; age range, 21–83 years; mean
age, 54.7 years) without any oral mucosal or sys-
temic diseases. All the patients and control sub-
jects were seen consecutively, diagnosed, and
treated in the Department of Oral Diagnosis of
National Taiwan University Hospital from July
2004 to February 2010. OLP patients with areca
quid chewing habit, hypertension, and autoim-
mune diseases such as systemic lupus erythema-
tosus, rheumatoid arthritis, Sjögren’s syndrome,
pemphigus vulgaris, and cicatricial pemphigoid
were excluded. In addition, none of them had
taken any prescription medication for at least 
3 months before entering the study. The 583
OLP patients included 512 with EOLP (93 men
and 419 women; age range, 22–88 years; mean
age, 55.3 years) and 71 with non-erosive OLP
(NEOLP) (9 men and 62 women; age range,
26–83 years; mean age, 52.9 years). They were
selected according to the following criteria: (1) a
typical clinical presentation of radiating grayish-
white Wickham striae, papules and plaques, sep-
arately or in combination (NEOLP), and erosion
or ulceration of the oral mucosa (EOLP); and (2)
biopsy specimens characteristic of OLP, that 
is, hyperkeratosis or parakeratosis, a slightly 
acanthotic epithelium with liquefaction degen-
eration of the basal epithelial cells, a pro-
nounced band-like lymphocytic infiltrate in the
lamina propria, and the absence of epithelial dys-
plasia. EOLP was further divided into major and
minor types according to previously described 
criteria.6–8
H.P. Lin, et al
318 J Formos Med Assoc | 2011 • Vol 110 • No 5
All OLP patients, regardless of their subtype,
were treated with levamisole that was adminis-
tered at a dose of 50 mg twice daily for patients
with 30–50 kg body weight, or 50 mg three times
daily for patients with 50–70 kg body weight, for
three consecutive days at the beginning of each
two-week interval. Compliance was monitored
by asking the patients to record the time at which
each drug was taken. Before the start of therapy,
clinical data on all cases were recorded according
to a set protocol, and the patients were examined
by the same dentist during each visit. Patients
were monitored once monthly to record clinical
responses after treatment.
Blood samples were taken from OLP patients
before treatment and from normal control subjects.
To assess whether the serum ANA levels in OLP
patients were reduced after treatment with levami-
sole, blood samples were obtained serially every
2–3 months until the serum ANA levels became
undetectable. Informed consent was obtained from
each patient or control subject before blood
sample collection. This study was reviewed and
approved by the Human Investigation Review
Committee at the National Taiwan University
Hospital.
Determination of serum ANA levels
Circulating ANA levels were detected by the indirect
immunofluorescence technique with Hep-2 cells
(Medical & Biological Laboratories Co., Nagaya,
Japan) as substrates, as described previously.13,15
Hep-2 cells on slides were reacted with serially
diluted OLP patients’ and control subjects’ sera,
in a moist chamber at room temperature for 30
minutes. The initial dilution of the patients’ and
control subjects’ sera was 1:20 with phosphate-
buffered saline (PBS). After washing with PBS, the
sections were incubated with fluorescein-isothio-
cyanate-labeled, goat anti-human IgG antiserum
(Boehringer Mannheim Biochemicals, Indiana-
polis, IN, USA), which had been prediluted and
kept in a dropper vial by the manufacturer, and
was ready-to-use for another 30 minutes. The sec-
tions were washed again, mounted with buffered
glycerine, and examined with an Olympus 
fluorescence microscope (Tokyo, Japan). Sera were
scored as positive for ANA when they produced
fluorescence at a dilution of 160-fold or more.
Statistical analysis
The difference in frequency of serum ANA was
compared between any two groups by the χ2 test.
The serum levels of ANA at baseline and after
treatment were compared to each other using a
paired t test. The result was considered to be sig-
nificant if the p value was < 0.05.
Results
One hundred and thirty-five OLP patients (23.2%)
had an ANA titer ≥ 160-fold in their sera. The fre-
quencies of serum ANA in different groups of
OLP patients and 53 healthy control subjects are
shown in Table 1. We found that the frequencies
of serum ANA in patients with OLP (23.2%, p =
0.005), EOLP (23.8%, p = 0.004), major EOLP
(31.5%, p = 0.000), and minor EOLP (18.1%,
p = 0.040) were all significantly higher than that
(5.7%) in healthy control subjects. In addition,
OLP patients > 50 years of age and male or female
Table 1. Frequencies of serum antinuclear antibody
in different groups of oral lichen planus
patients and 53 healthy control subjects
ANA positive 
Groups patient p
number (%)
OLP (n = 583) 135 (23.2) 0.005a
≤ 50 yr (n = 185) 31 (16.8) 0.070a
> 50 yr (n = 398) 104 (26.1) 0.002a
Male (n = 102) 21 (20.6) 0.028a
Female (n = 481) 114 (23.7) 0.005a
EOLP (n = 512) 122 (23.8) 0.004a
Major type (n = 219) 69 (31.5) 0.000a
Minor type (n = 293) 53 (18.1) 0.040a
NEOLP (n = 71) 13 (18.3) 0.071a
Healthy controls (n = 53) 3 (5.7)
aComparison between healthy control and any other groups by 
c2 test. ANA = antinuclear antibody; EOLP = erosive oral lichen
planus; NEOLP = non-erosive oral lichen planus.
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patients also had a significant higher frequency
of serum ANA than healthy control subjects had
(Table 1). Moreover, OLP patients > 50 years of
age had a significantly higher frequency of serum
ANA (26.1%) than those aged ≤ 50 years (16.8%,
p = 0.017, Table 2). In addition, major EOLP 
patients had a significantly higher frequency of
serum ANA (31.5%) than minor EOLP (18.1%,
p = 0.000) or NEOLP (18.3%, p = 0.046, Table 2)
patients had.
Of 135 ANA-positive OLP patients, 79 were
treated with levamisole under a regular follow-
up schedule in our dental clinic. We found that
treatment with levamisole for a period of 2–38
months (mean, 12±9 months) effectively reduced
the high mean serum ANA level (557 ± 98) at
baseline to an undetectable level (0) in all 79
ANA-positive OLP patients, including those with
EOLP, major or minor EOLP, and NEOLP (Table 3).
Furthermore, when OLP patients were divided
into five different groups according to different
initial serum ANA titers that ranged from 1:40 to
1:5120, all the high serum ANA levels at baseline
were effectively reduced to an undetectable level
(0, all p values = 0.000) after treatment with lev-
amisole for 2–38 months (Table 3). Moreover,
OLP patients with higher ANA titers usually re-
quired longer treatment duration to reduce ANA
titer to an undetectable level than did those with
lower ANA titers (Table 3). The 79 ANA-positive
OLP patients also had significant improvement
in signs and symptoms of OLP after levamisole
treatment for 2–38 months (such as a reduction
in lesion size and pain caused by the lesion, heal-
ing of erosive or ulcerative lesions, and transfor-
mation of EOLP into NEOLP).
Discussion
This study showed a serum ANA-positive rate of
23.2% in 583 OLP patients. Our previous study
demonstrated the presence of serum ANA in 28.1%
of 320 OLP patients.15 We suggest that the differ-
ence in the serum ANA-positive rate between these
two groups of OLP patients was due to different
sample sizes in these two studies. In the present
study, we treated the OLP patients with levamisole
and found that serum ANA was reduced to an un-
detectable level after treatment for 2–38 months,
regardless of different high initial serum titers of
ANA. Our previous studies also have shown the
disappearance of serum anti-BCA in three of six
anti-BCA-positive EOLP patients and the disap-
pearance of serum ANA in three ANA-positive
EOLP patients after levamisole treatment.9 In ad-
dition, treatment with levamisole for 0.5–7.5
months can significantly reduce the abnormally
high serum IL-6, IL-8 and TNF-α levels to normal in
patients with OLP or EOLP.7,8 The most impor-
tant factor is that the reduction of autoantibody
or cytokine levels after levamisole treatment is
always accompanied by significant improvement
of signs and symptoms in OLP patients.6–9 These
findings suggest that levamisole treatment shifts
the abnormal serum autoantibody and cytokine
levels to normal in OLP patients, and is an effec-
tive treatment modality for OLP.
Table 2. Comparison of serum antinuclear
antibody positivity between different
groups of oral lichen planus patients
ANA (+) ANA (−) p
(n = 135) (n = 448) (χ2 test)
Age (yr) 0.017
≤ 50 (n = 185) 31 154
> 50 (n = 398) 104 294
Sex 0.584
Male (n = 102) 21 81
Female (n = 481) 114 367
OLP type 0.377
EOLP (n = 512) 122 390
NEOLP (n = 71) 13 58
EOLP type 0.000
Major (n = 219) 69 150
Minor (n = 293) 53 240
OLP type 0.046
Major EOLP 69 150
(n = 219)
NEOLP (n = 71) 13 58
ANA = antinuclear antibody; EOLP = erosive oral lichen planus;
NEOLP = non-erosive oral lichen planus.
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Previous studies have demonstrated an over-
all incidence of 27–82% for serum autoantibod-
ies in several different groups of OLP or EOLP
patients.9–15 Serum anti-BCA was found in 34
(54%) of 63 OLP patients.10 Serum autoantibod-
ies including rheumatoid factor, ANA and SMA
were demonstrated in 27% of 30 OLP patients
and in 9% of 23 control subjects.11 The presence
of circulating antibodies to epithelial antigen
was shown in 57% of 14 hepatitis C virus anti-
body (HCVA)-positive OLP patients and in none
of 14 HCVA-negative patients.12 Carrozzo et al13
discovered the presence of serum autoantibod-
ies, including ANA, SMA, AMA, GPCA, and anti-
thyroid antibody in 41% of 27 HCVA-positive
OLP patients and in 52% of 23 HCVA-negative
patients. Lukac et al14 demonstrated by enzyme-
linked immunosorbent assay significantly higher
concentrations of circulating autoantibodies to
desmogleins 1 and 3 in 32 EOLP patients com-
pared with 50 healthy controls. Indirect immu-
nofluorescence also revealed significantly higher
frequencies of desmoglein autoantibodies in EOLP
patients (82%, 18/22) than in healthy controls
(5%, 1/20). Our recent study showed an overall
incidence of 60.9% for the presence of serum auto-
antibodies in a large group of 320 OLP patients,
and significantly higher frequencies of serum
ANA, GPCA, TGA and TMA in OLP patients than
in healthy control subjects.15 The above findings
suggest that there are significantly higher frequen-
cies of serum autoantibodies in OLP patients than
in healthy control subjects.
The present study showed a significantly higher
serum ANA positive rate in major EOLP than in
minor EOLP or NEOLP patients. Major EOLP le-
sions caused greater destruction of oral mucosa
and therefore might have released more nuclear
antigens into the local tissues and blood circula-
tion than did minor EOLP or NEOLP lesions.
These nuclear antigens could have been phago-
cytosed and processed by macrophages and B
cells, and in turn, presented to helper/inducer T
cells in the oral mucosal lesions, regional lymph
nodes, and blood circulation of OLP patients.
With the help of T cells, antigen-specific acti-
vated B cells thus produced high levels of ANA 
in the local oral mucosal lesions and blood cir-
culation of OLP patients. In addition, our recent
study also has shown that HCVA positivity and
Table 3. Serum titers of antinuclear antibody before and after treatment with levamisole in 79 oral lichen
planus patients, including 36 with major and 35 with minor erosive oral lichen planus, and eight
with non-erosive oral lichen planus
Duration of Serum titers of ANA 
Treatment treatment (mo) (Fold of dilution of serum)
modality Patient type or ANA titer
Range Mean ± SD
At baseline After treatment
pa
Mean ± SEM Mean ± SEM
Levamisole OLP (n = 79) 2–38 12 ± 9 557 ± 98 0 0.000
Levamisole EOLP (n = 71) 2–38 12 ± 9 578 ± 108 0 0.000
Levamisole Major type (n = 36) 2–38 14 ± 10 828 ± 183 0 0.000
Levamisole Minor type (n = 35) 2–38 9 ± 8 321 ± 98 0 0.002
Levamisole NEOLP (n = 8) 4–29 14 ± 8 370 ± 147 0 0.040
Levamisole ANA titer ≥ 1280 (n = 11) 13–38 24 ± 9 2444 ± 321 0 0.000
Levamisole ANA titer = 640 (n = 11) 8–32 19 ± 8 640 0 0.000
Levamisole ANA titer = 320 (n = 23) 5–29 13 ± 7 320 0 0.000
Levamisole ANA titer = 160 (n = 8) 2–15 6 ± 5 160 0 0.000
Levamisole ANA titer ≤ 80 (n = 26) 2–12 5 ± 2 55 ± 4 0 0.000
aComparison of serum ANA titers between patients at baseline and after treatment by paired t test. ANA = antinuclear antibody;
SD = standard deviation; SEM = standard error of the mean; OLP = oral lichen planus; EOLP = erosive oral lichen planus; NEOLP = non-
erosive oral lichen planus.
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TGA/TMA positivity are another two risk factors
that contribute to the presence of serum ANA in
OLP patients.15 HCVA-positive and TGA/TMA-
positive OLP patients may also have underlying
chronic liver and autoimmune thyroid diseases,
respectively. Therefore, they can have more 
nuclear antigens released in the local liver and
thyroid tissues and blood circulation. By similar
mechanisms, these released nuclear antigens
may stimulate the antigen-specific activated B
cells to produce more ANA. The locally produced
autoantibodies in the interstitial fluid may dif-
fuse into blood capillaries or be drained into the
lymphatic vessels, and finally reach the blood
circulation. The locally secreted ANA, together
with that produced in the blood circulation even-
tually give rise to significantly higher levels of
serum ANA in OLP patients than in healthy con-
trol subjects. The disappearance of the serum anti-
BCA antibodies and ANA after treatment-induced
healing of the OLP lesions in previous studies9,10
and in the present study also suggests that the
principal autoantigens come from the local OLP
lesions.
In conclusion, there was a significantly higher
frequency of serum ANA (23.2%) in Taiwanese
OLP patients than in healthy control subjects.
Treatment with levamisole for 2–38 reduced the
high serum ANA concentrations to undetectable
levels, and significantly improved signs and symp-
toms of OLP patients. Therefore, we conclude
that levamisole treatment can modulate the high
serum ANA titer to undetectable levels in OLP
patients, and is an effective treatment modality
for OLP.
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